Latest News on CRMD

Financial News Based On Company


Advertisement
Advertisement

Insider Buying: CorMedix (NASDAQ:CRMD) Director Purchases 25,000 Shares of Company Stock

https://www.marketbeat.com/instant-alerts/insider-insider-buying-cormedix-nasdaq-crmd-director-purchases-25000-shares-of-company-stock-2026-11-18/
CorMedix (NASDAQ:CRMD) Director Myron Kaplan recently purchased 25,000 shares of the company's stock for $122,000, increasing his stake by 10.8%. Despite the insider buying, CorMedix shares fell 3.6% to $4.50, and the company reported a wider-than-expected quarterly loss of $0.19 per share, though revenue exceeded estimates. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $15.22.

After buying 25,000 shares, CorMedix (CRMD) director Myron Kaplan holds 256,487 shares directly.

https://www.stocktitan.net/sec-filings/CRMD/form-4-cor-medix-inc-insider-trading-activity-bf11c8555ff2.html
CorMedix Inc. director Myron Kaplan purchased 25,000 shares of common stock on November 16, 2026, at a weighted-average price of $4.88 per share. Following this transaction, his direct holdings total 256,487 shares. Kaplan also reported indirect holdings via his spouse and spouse as guardian for grandchildren, though he disclaims beneficial ownership of these securities.

CEO & Chairman of the Board of Directors of CorMedix Joseph Todisco Buys 20% More Shares

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crmd/cormedix/news/ceo-chairman-of-the-board-of-directors-of-cormedix-joseph-to
CorMedix Inc.'s CEO & Chairman, Joseph Todisco, recently purchased US$391k worth of company stock, increasing his holding by 20%. While there was a significant insider sale by an independent director in the last year, the recent purchase indicates some alignment between management and shareholders, with insiders owning 7.3% of the company's shares. The article notes the recent purchase as positive, despite a less favorable overall insider transaction history over the past year.

CorMedix (NASDAQ:CRMD) Stock: Insider Joseph Todisco Buys 80,000 Shares

https://www.marketbeat.com/instant-alerts/insider-cormedix-nasdaq-crmd-stock-insider-joseph-todisco-buys-80000-shares-2026-11-16/
CorMedix CEO Joseph Todisco recently purchased 80,000 shares of CRMD stock for $391,200, increasing his direct ownership by over 10%. Despite missing EPS estimates with -$0.19, the company exceeded revenue expectations at $54.52 million. Analysts currently rate CorMedix as a "Moderate Buy" with an average price target of $15.22, significantly above its current trading price near its 12-month low.

Form 4 CorMedix Inc: Joseph Todisco (Director, CEO) For: 13 November

https://in.investing.com/news/stock-market-news/form-4-cormedix-inc-joseph-todisco-director-ceo-for-13-november-93CH-5706889
This article reports on a Form 4 filing for CorMedix Inc., detailing an insider transaction by Joseph Todisco, who holds positions as Director and CEO. The filing is specifically for November 13th. The brief announcement provides no further details about the nature or value of the transaction.
Advertisement

CorMedix (CRMD) CEO buys at $4.89 a share, bringing direct holdings to 854,749 shares.

https://www.stocktitan.net/sec-filings/CRMD/form-4-cor-medix-inc-insider-trading-activity-40934ca6cf8c.html
CorMedix Inc.'s CEO, Joseph Todisco, purchased 80,000 shares of common stock on November 13, 2026, at a weighted-average price of $4.89 per share. This transaction increased his direct holdings to 854,749 shares. The insider trade, valued at approximately $391,000, was executed in multiple trades ranging from $4.85 to $5.00 per share.

CorMedix Reports $54.5M Q3 Revenue, Raises EBITDA Guidance and Advances Heron Deal

https://www.tradingview.com/news/tradingview:d839d23b84be2:0-cormedix-reports-54-5m-q3-revenue-raises-ebitda-guidance-and-advances-heron-deal/
CorMedix reported third-quarter 2026 revenue of $54.5 million and narrowed its full-year adjusted EBITDA guidance to $130 million–$140 million. The company expects its proposed acquisition of Heron assets to close in Q1 2027, projecting $125 million–$150 million in pro forma 2027 revenue from acquired products and $45 million–$60 million in annualized cost synergies. While the FDA accepted REZZAYO's prophylaxis sNDA for priority review, the DefenCath TPN study enrollment is behind schedule, prompting evaluation of alternative approval pathways.

Form 4 CorMedix Inc: Joseph Todisco (Director, CEO) For: 13 November

https://ca.investing.com/news/stock-market-news/form-4-cormedix-inc-joseph-todisco-director-ceo-for-13-november-93CH-4960812
This article reports on a Form 4 filing for CorMedix Inc., detailing insider transaction information for Joseph Todisco, who serves as a Director and CEO of the company. The filing is dated November 13, 2026. The stock symbol for CorMedix Inc. is CRMD.

CRMD Stock Down 9% Despite Q3 Earnings and Revenues Beat Estimates

https://www.tradingview.com/news/zacks:329445336094b:0-crmd-stock-down-9-despite-q3-earnings-and-revenues-beat-estimates/
CorMedix (CRMD) reported a narrower-than-expected adjusted loss of 4 cents per share in Q3 2026 and beat revenue estimates with $54.5 million, though revenues declined significantly year-over-year due to lower DefenCath pricing post-TDAPA. Despite the beats, CRMD stock dropped 8.7% due to concerns over reduced DefenCath prices. The company maintained its full-year revenue guidance and narrowed its EBITDA outlook, while also making key strategic moves including the acquisition of Heron Therapeutics assets and progress on Rezzayo's supplemental NDA.

CorMedix (NASDAQ:CRMD) Releases Earnings Results, Misses Expectations By $0.07 EPS

https://www.marketbeat.com/instant-alerts/earnings-cormedix-nasdaq-crmd-releases-earnings-results-misses-expectations-by-007-eps-2026-11-12/
CorMedix (NASDAQ:CRMD) reported quarterly earnings of ($0.19) per share, missing consensus estimates by $0.07, despite revenue of $54.52 million exceeding expectations. The company also announced the acquisition of most of Heron Therapeutics' assets, projecting $125 million–$150 million in 2027 revenue and significant cost synergies. Despite maintaining its 2026 revenue outlook, CorMedix faces delays in its DefenCath phase III TPN study and has not yet provided 2027 product guidance.
Advertisement

What CorMedix (CRMD) Said on Its Q3 Earnings Call

https://www.tradingview.com/news/marketbeat:aab586f71094b:0-what-cormedix-crmd-said-on-its-q3-earnings-call/
CorMedix (CRMD) reported reduced third-quarter revenue and a net loss, primarily due to its DefenCath product entering a new, lower reimbursement period. The company reaffirmed its 2026 revenue outlook but deferred 2027 guidance for DefenCath, citing uncertainty around quarterly reimbursement adjustments. Additionally, CorMedix outlined plans to acquire assets from Heron Therapeutics to diversify its revenue streams and reduce reliance on DefenCath.

Cormedix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

https://www.stocktitan.net/news/CRMD/cormedix-therapeutics-reports-third-quarter-2026-financial-results-zj7slkgupfxb.html
CorMedix Therapeutics reported consolidated revenue of $54.5 million for Q3 2026, a decrease from the prior year, and a net loss of $14.7 million. The company maintained its 2026 revenue guidance but suspended 2027 DefenCath revenue guidance due to CMS reimbursement changes. CorMedix anticipates the acquisition of Heron Therapeutics assets to close in Q1 2027, which is expected to contribute $125–$150 million to 2027 revenue and be immediately accretive to earnings and free cash flow.

Cormedix Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/63186097/cormedix-q3-2026-earnings-call-transcript
Cormedix Inc. announced a definitive agreement to acquire Heron Therapeutics' assets, expecting to double their revenue base and achieve significant cost synergies by the end of 2027. For Q3 2026, Cormedix reported consolidated revenue of $54.5 million and adjusted EBITDA of $3.1 million, reaffirming 2026 revenue guidance and narrowing adjusted EBITDA guidance. The company is navigating uncertainties with DefenCath's 2027 reimbursement and advancing its pipeline, including FDA's priority review for REZZAYO's sNDA for prophylaxis.

CORMEDIX ($CRMD) Releases Q3 2026 Earnings

https://www.quiverquant.com/news/CORMEDIX+%28%24CRMD%29+Releases+Q3+2026+Earnings
CORMEDIX ($CRMD) announced its Q3 2026 earnings, reporting -$0.04 per share, surpassing analyst estimates of -$0.11. The company also exceeded revenue expectations with $54,520,000 against estimates of $54,291,366. Institutional investor activity showed a mixed sentiment with 95 firms adding shares and 88 decreasing their positions in the most recent quarter.

Cormedix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

https://www.globenewswire.com/news-release/2026/11/12/3401467/0/en/cormedix-therapeutics-reports-third-quarter-2026-financial-results-and-provides-business-update.html
CorMedix Therapeutics reported its third-quarter 2026 financial results, including consolidated revenue of $54.5 million and a net loss of $14.7 million. The company announced a pending acquisition of Heron Therapeutics' assets, expected to double non-DefenCath annual product revenue and be immediately accretive to earnings and free cash flow. Additionally, the FDA accepted for review an sNDA for REZZAYO for the prophylaxis of invasive fungal disease, with an anticipated agency action in Q1 2027.
Advertisement

CorMedix Beats A Lowered Bar As The DefenCath Cliff Arrives, And Heron Becomes The New Growth Story

https://finviz.com/news/421912/cormedix-beats-a-lowered-bar-as-the-defencath-cliff-arrives-and-heron-becomes-the-new-growth-story
CorMedix (CRMD) reported a Q3 earnings beat, exceeding expectations for both loss per share and revenue, but faced a significant decline in its DefenCath revenue. The company is pivoting towards an acquisition-led diversification strategy with the Heron acquisition, aiming to offset the collapsing DefenCath franchise. Despite reaffirming full-year 2026 revenue guidance and raising Adjusted EBITDA guidance, the long-term outlook for DefenCath remains uncertain, and the market has reacted negatively to the withdrawal of 2027 DefenCath guidance and acquisition risks.

CorMedix: Q3 Earnings Snapshot

https://www.kens5.com/article/syndication/associatedpress/cormedix-q3-earnings-snapshot/616-1767ee74-0b4b-41e9-b6da-82d933f6afc7
CorMedix Inc. (CRMD) reported a third-quarter loss of $14.7 million, or 19 cents per share. Adjusted for merger and acquisition costs, losses were 4 cents per share. The pharmaceutical and medical device company posted revenue of $54.5 million and expects full-year revenue between $325 million and $345 million.

Key facts: CorMedix Heron Deal; $145M Funding; RBC Raises Target to $15

https://www.tradingview.com/news/tradingview:e23a5598eab8c:0-key-facts-cormedix-heron-deal-145m-funding-rbc-raises-target-to-15/
CorMedix (CRMD) has agreed to acquire key assets from Heron Therapeutics, which would add approximately $150 million in trailing revenue. The deal, expected to close in Q1 2027, will be funded by $70 million in cash and a $75 million draw from a new $150 million term loan. Following this news, RBC Capital maintained its Outperform rating on CorMedix and increased its price target from $14 to $15.

CRMD: CorMedix agrees to buy substantially all assets of Heron

https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-cormedix-inc-6784701
CorMedix Inc. has announced a definitive agreement to acquire substantially all assets of Heron Therapeutics, including four FDA-approved commercial brands. This acquisition is expected to diversify CorMedix's revenue and be accretive to its earnings, though it will involve issuing shares to Heron in a private placement, leading to some dilution for existing stockholders. The deal is subject to customary closing conditions.

CorMedix Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

https://www.quantisnow.com/insight/cormedix-inc-filed-sec-form-8-k-regulation-fd-disclosure-financial-6784692
CorMedix Inc. has filed an SEC Form 8-K announcing a definitive asset purchase agreement to acquire substantially all of Heron Therapeutics' assets. The deal involves an upfront cash consideration of $145 million, the issuance of 14,583,333 shares of CorMedix common stock, and potential earn-out payments of up to $55 million. This acquisition aims to expand CorMedix's product portfolio with four FDA-approved commercial brands and diversify its revenue base.
Advertisement

CorMedix to Acquire Heron Assets, Adding Four Products and Targeting Up to $60 Million in Savings

https://www.tradingview.com/news/marketbeat:e093e063a094b:0-cormedix-to-acquire-heron-assets-adding-four-products-and-targeting-up-to-60-million-in-savings/
CorMedix has agreed to acquire substantially all of Heron Therapeutics' assets, including four commercial products and a development agreement, for $145 million in cash and approximately 14.6 million shares of its common stock upfront. The deal is expected to be immediately accretive to earnings and free cash flow and generate $45 million to $60 million in annualized operating cost synergies by the end of 2027. The acquired portfolio includes treatments for postoperative pain, nausea and vomiting, and chemotherapy-induced nausea and vomiting.

REG - BioPharma Credit PLC - NEW INVESTMENT OF UP TO US$50M IN CORMEDIX INC.

https://www.tradingview.com/news/reuters.com,2026-11-10:newsml_RSJ4370Ca:0-reg-biopharma-credit-plc-new-investment-of-up-to-us-50m-in-cormedix-inc/
BioPharma Credit PLC announced a new senior secured loan agreement with CorMedix Inc., committing up to US$50 million as part of a total US$150 million facility. This investment supports CorMedix's acquisition of substantially all of Heron Therapeutics, Inc.'s assets, including four commercial-stage products. The acquisition is expected to close in Q1 2027, with the loan funds disbursed in two tranches.

Why Heron Therapeutics Stock is Surging on Monday - Heron Therapeutics (NASDAQ:HRTX), Cormedix (NASDAQ:CR

https://www.benzinga.com/m-a/26/11/63051078/cormedix-bolsters-hospital-pipeline-via-heron-therapeutics-asset-deal
Heron Therapeutics (NASDAQ:HRTX) stock surged on Monday after CorMedix Therapeutics (NASDAQ:CRMD) announced its acquisition of substantially all of Heron's assets for approximately $222.6 million. The deal will expand CorMedix's hospital and surgical center commercial portfolios by adding four commercial-stage therapies, including ZYNRELEF for postoperative pain. The transaction involves cash, equity terms, and potential milestone payments and royalties for Heron.

CorMedix stock gains as Heron deal adds four products

https://www.investing.com/news/stock-market-news/cormedix-stock-gains-as-heron-deal-adds-four-products-5012105
CorMedix Inc. shares rose in premarket trading after announcing the acquisition of Heron Therapeutics Inc.'s assets for approximately $222.6 million. This deal adds four commercial-stage products to CorMedix's portfolio, enhancing its hospital and acute-care platform. CorMedix expects the transaction to be immediately accretive to earnings and free cash flow, with significant operating cost synergies anticipated by year-end 2027.

CorMedix to Acquire Heron Therapeutics Assets for $145 Million in Cash and 14.6 Million Shares

https://www.tradingview.com/news/tradingview:c6e0cca2a9e9a:0-cormedix-to-acquire-heron-therapeutics-assets-for-145-million-in-cash-and-14-6-million-shares/
CorMedix has agreed to acquire substantially all of Heron Therapeutics' assets for $145 million in cash and 14.6 million CorMedix shares, with potential additional royalties and earn-outs. The acquisition is contingent on Heron stockholder approval and customary closing conditions. CorMedix has also secured a senior secured loan facility of up to $150 million to help fund the transaction.
Advertisement

CRMD: CorMedix to buy Heron assets for $145.0M cash and 14.6M shares

https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-cormedix-inc-6780291
CorMedix has agreed to acquire substantially all assets of Heron Therapeutics for $145.0 million in cash, 14.6 million shares, 5% royalties, and up to $55 million in earn-outs. This transaction is expected to be accretive to CorMedix's earnings and will add four FDA-approved commercial brands to its revenue base, although it will dilute existing shareholders through the issuance of new shares and require new debt financing.

CorMedix Therapeutics to Acquire Substantially All Assets

https://www.globenewswire.com/news-release/2026/11/09/3398281/0/en/cormedix-therapeutics-to-acquire-substantially-all-assets-of-heron-therapeutics-expanding-its-portfolio-of-products-used-in-institutional-settings-of-care.html
CorMedix Therapeutics is set to acquire substantially all assets of Heron Therapeutics for $145 million in cash, 14,583,333 shares of CorMedix common stock, and up to $55 million in earn-out payments and royalties. This acquisition adds four commercial-stage products to CorMedix's portfolio, expanding its presence in institutional settings of care and is expected to be immediately accretive to CorMedix's earnings and free cash flow. The transaction is anticipated to close in the first quarter of 2027, subject to regulatory clearance and Heron stockholder approval.

CorMedix Therapeutics to Acquire Substantially All Assets

https://www.globenewswire.com/news-release/2026/11/09/3398250/0/en/cormedix-therapeutics-to-acquire-substantially-all-assets-of-heron-therapeutics-expanding-its-portfolio-of-products-used-in-institutional-settings-of-care.html
CorMedix Therapeutics is set to acquire substantially all assets of Heron Therapeutics, a move that will expand CorMedix's portfolio with four commercial-stage products used in institutional settings of care. The transaction, valued at $145 million in cash, 14,583,333 shares of CorMedix common stock, and up to $55 million in earn-out payments and royalties, is expected to be immediately accretive to CorMedix's earnings and free cash flow. This strategic acquisition aims to leverage existing commercial infrastructure and generate significant operating cost synergies.

CorMedix, Inc. (CRMD) Seasonal returns chart

https://uk.finance.yahoo.com/quote/CRMD/seasonality/
This article provides a seasonal returns chart for CorMedix, Inc. (CRMD), displaying the average monthly price return from 2016 to 2026. It also includes current stock price data and after-hours trading information for CRMD.

An 8:30 a.m. update call is set for Nov. 12, when CorMedix reports quarterly results.

https://www.stocktitan.net/news/CRMD/cor-medix-therapeutics-to-report-third-quarter-2026-financial-30424a4iwfry.html
CorMedix Therapeutics (Nasdaq: CRMD) announced it will report its third-quarter 2026 financial results before the market opens on November 12, 2026. The company will also host a corporate update conference call at 8:30 a.m. Eastern Standard Time on the same day. These results cover the quarter ended September 30, 2026.
Advertisement

CorMedix Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026

https://www.globenewswire.com/news-release/2026/11/06/3397502/0/en/cormedix-therapeutics-to-report-third-quarter-2026-financial-results-and-provide-a-corporate-update-on-november-12-2026.html
CorMedix Therapeutics (Nasdaq: CRMD) announced it will report its financial results for the third quarter ended September 30, 2026, before the market opens on Thursday, November 12, 2026. The company will also host a corporate update conference call at 8:30 a.m. Eastern Standard Time on the same day. This update comes after a recent business update and reaffirmation of 2026 total revenue guidance, as well as an FDA acceptance for Priority Review of a supplemental NDA for Rezzayo®.

CorMedix Backs 2026 Rev $325M-$355M >CRMD

https://www.moomoo.com/news/post/1003189200/cormedix-backs-2026-rev-325m-355m-crmd
CorMedix is projecting strong revenue growth for 2026, backing a range of $325 million to $355 million. This outlook suggests the company anticipates significant expansion in its market presence and product sales.

CorMedix reaffirms 2026 revenue guidance, reports $355M cash

https://www.streetinsider.com/Corporate+News/CorMedix+reaffirms+2026+revenue+guidance,+reports+$355M+cash/27269710.html
CorMedix Therapeutics reaffirmed its full-year 2026 total revenue guidance of $325 million to $345 million and reported $355 million in cash as of September 30, 2026. The company also clarified the 2027 DefenCath add-on payment rate of $8.32 per dialysis session, stating it expects the rate to fluctuate but exceed the current $2.37 rate on average for the full year. CorMedix cautioned investors against third-party projections for future quarterly add-on payments.

Form 8K CorMedix Inc For: 2 November By Investing.com

https://ng.investing.com/news/stock-market-news/form-8k-cormedix-inc-for-2-november-93CH-2774790
The article reports on CorMedix Inc.'s (CRMD) Form 8K filing for November 2nd, indicating a significant corporate event. The stock experienced a 3.15% increase, suggesting a positive market reaction to the filing. No specific details of the Form 8K content are provided within this brief announcement.

Form 8K CorMedix Inc For: 2 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-8k-cormedix-inc-for-2-november-93CH-4949145
This Investing.com article reports on CorMedix Inc.'s Form 8K filing for November 2nd. The article provides the title and a brief mention of the company and filing date, alongside various market data and news headlines. It highlights CRMD's stock performance and lists several popular articles related to market trends and analyst insights.
Advertisement

CorMedix Therapeutics Provides Business Update, Reaffirms

https://www.globenewswire.com/news-release/2026/11/02/3393044/0/en/cormedix-therapeutics-provides-business-update-reaffirms-2026-total-revenue-guidance-and-reports-third-quarter-cash-position.html
CorMedix Therapeutics provided a business update, reaffirming its 2026 total revenue guidance of $325 million to $345 million and reporting approximately $355 million in cash and cash equivalents as of September 30, 2026. The company also addressed the 2027 End-Stage Renal Disease Prospective Payment System final rule, which sets a post-TDAPA Add-on for DefenCath of $8.32 per dialysis session for Q1 2027, and countered third-party projections regarding future quarterly adjustments. CorMedix expects to host a conference call on November 12, 2026, to discuss its complete quarterly financial performance.

Form 8K CorMedix Inc For: 2 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-cormedix-inc-for-2-november-93CH-4921942
This article announces that CorMedix Inc. filed a Form 8K on November 2, 2026. The filing is a standard SEC disclosure document, but no specific details of the Form 8K's content are provided within this brief notice. The article primarily serves as a notification of the filing.

CorMedix reaffirms 2026 revenue guidance, reports $355M cash

https://www.streetinsider.com/Corporate+News/CorMedix+reaffirms+2026+revenue+guidance%2C+reports+%24355M+cash/27269710.html
CorMedix (NASDAQ: CRMD) reaffirmed its 2026 full-year revenue guidance, expecting between $325 million and $345 million. The company also reported approximately $355 million in unaudited cash and cash equivalents as of September 30, 2026. CorMedix provided details on the 2027 DefenCath add-on payment rate and clarified its stance on third-party projections, anticipating a decline in the add-on in Q2 2027 followed by an increase later in the year.

A federal rule sets an $8.32 add-on payment per DefenCath dialysis session in Q1 2027.

https://www.stocktitan.net/news/CRMD/cor-medix-therapeutics-provides-business-update-reaffirms-2026-total-trysqxw7l9do.html
CorMedix Therapeutics reaffirmed its full-year 2026 revenue guidance of $325 million to $345 million and reported approximately $355 million in cash and cash equivalents as of September 30, 2026. The company announced that CMS has set the Q1 2027 DefenCath add-on payment at $8.32 per dialysis session, significantly higher than the $2.37 rate for Q3 and Q4 2026. CorMedix expects the add-on to decline in Q2 2027 but increase in Q3 and/or Q4, with all 2027 quarterly rates projected to exceed $2.37.

Form 8-K CorMedix Inc. For: Nov 02

https://www.streetinsider.com/SEC+Filings/Form+8-K+CorMedix+Inc.+For%3A+Nov+02/27269746.html
CorMedix Inc. filed a Form 8-K on November 2, 2026, announcing its cash position for the quarter ended September 30, 2026, via a press release. This report includes information regarding results of operations and financial condition, as well as a business update. The filing also contains forward-looking statements subject to various risks and uncertainties.
Advertisement

CRMD Slides Sharply As Traders Eye Support Levels

https://stockstotrade.com/news/cormedixinc-crmd-news-2026_11_01/
CorMedix Inc. (CRMD) stock dropped sharply by 24.81% due to concerns over its latest clinical trial developments, pushing the price from above $8 to the mid-$5s. Despite the technical downturn and aggressive selling, the company maintains strong fundamental backing with high gross margins, explosive revenue growth, and a solid balance sheet. Analysts suggest the market is excessively discounting execution and regulatory risks, anticipating a reversion towards $6.75–$7.25 over the next 6–12 months.

CRMD Slides As Traders React To Sharp Volume Shift

https://timothysykes.com/news/cormedixinc-crmd-news-2026_11_01/
CorMedix Inc. (CRMD) stock has dropped by 24.81% due to concerns over its latest regulatory and clinical developments, despite strong financial fundamentals. While technical indicators show a sharp breakdown and emerging bearish trend, an analyst maintains a constructive outlook with a fair value target of $10–11 based on the company's robust profitability and balance sheet. The market appears to be pricing in an overly bearish scenario, suggesting a potential disconnect between price action and underlying value.

Understanding Momentum Shifts in (CRMD)

https://news.stocktradersdaily.com/news_release/1/Understanding_Momentum_Shifts_in_CRMD_102726065602_1793098562.html
Cormedix Inc. (NASDAQ: CRMD) is showing strong near and mid-term sentiment, although its long-term outlook appears weak. AI models suggest three distinct trading strategies, including a Position Trading Strategy with a target of $8.88 and a Momentum Breakout Strategy with a trigger of $8.20. The article highlights an exceptional 84.0:1 risk-reward setup, targeting a 23.3% gain versus 0.3% risk.

Weekly Recap: REZZAYO sNDA Priority Review and Needham $15 Buy

https://www.tradingview.com/news/tradingview:884530148bddf:0-weekly-recap-rezzayo-snda-priority-review-and-needham-15-buy/
CorMedix Inc. (NASDAQ:CRMD) received FDA Priority Review for REZZAYO's sNDA as a prophylactic in adult allogeneic HSCT, with a PDUFA target in Q1 2027 following positive Phase III results. Concurrently, Needham maintained a Buy rating and a $15 price target for CRMD, suggesting approximately 106.6% potential upside.

CorMedix Inc. Estimates – NASDAQ:CRMD

https://www.tradingview.com/symbols/NASDAQ-CRMD/financials-estimates/
This page provides financial actuals and analyst estimates for CorMedix Inc. (NASDAQ: CRMD), allowing users to explore reported financial data and compare actual results with average, high, and low estimates across various financial statements and valuation metrics. It highlights trends over time for income statements, balance sheets, and cash flow, as well as dividend and earnings information. The platform also offers disclaimers stating that the information is not investment advice.
Advertisement

CorMedix Inc. Estimates – GETTEX:19KA

https://www.tradingview.com/symbols/GETTEX-19KA/financials-estimates/?category=balance_sheet
This page provides an overview of CorMedix Inc. (19KA) financial estimates and actuals on Gettex via TradingView. Users can explore reported financial data and analyst estimates across various statements and metrics. It emphasizes that the content is not investment advice and encourages users to conduct their own research.

Leerink Partners Maintains CorMedix(CRMD.US) With Buy Rating, Raises Target Price to $16

https://www.moomoo.com/news/post/1001736715/leerink-partners-maintains-cormedix-crmdus-with-buy-rating-raises-target
Leerink Partners has reiterated its Buy rating on CorMedix (CRMD.US) and increased its target price for the stock to $16. This signals a continued positive outlook from the firm regarding CorMedix's future performance.

Needham & Company LLC Reaffirms "Buy" Rating for CorMedix (NASDAQ:CRMD)

https://www.marketbeat.com/instant-alerts/analyst-needham-company-llc-reaffirms-buy-rating-for-cormedix-nasdaq-crmd-2026-10-19/
Needham & Company LLC has reiterated its "Buy" rating for CorMedix (NASDAQ:CRMD), setting a $15.00 price target that suggests a 103.25% potential upside. Other analysts, including Royal Bank of Canada and Oppenheimer, have also issued "outperform" or "buy" ratings with similar price targets. The company recently reported strong quarterly earnings, beating analyst estimates, and institutional investors have been actively increasing their positions in the stock.

CorMedix Announces FDA Acceptance for Priorit

https://www.moomoo.com/news/flash/1001580994/cormedix-announces-fda-acceptance-for-priority-review-of-supplemental-nda
This article announces that CorMedix has received FDA acceptance for priority review of an unspecified application. The acceptance signifies a faster review process by the FDA, indicating the potential importance or novelty of the product.

A weekly antifungal is under priority review to prevent fungal disease during stem-cell transplants

https://www.stocktitan.net/news/CRMD/cormedix-announces-fda-acceptance-for-priority-review-of-m9dblecxffym.html
CorMedix Therapeutics announced that the FDA has granted Priority Review to its supplemental New Drug Application (sNDA) for REZZAYO® (rezafungin for injection). This sNDA seeks approval for the prophylaxis of invasive fungal disease, particularly in adults undergoing allogeneic hematopoietic stem cell transplantation. The FDA's target action date for this review is Q1 2027, with potential promotional efforts planned for H2 2027 if approved.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement